Evidence map›Paper›PMID 21757709›Full record

ArticleThe Journal of biological chemistry2011

A novel intronic cAMP response element modulator (CREM) promoter is regulated by activator protein-1 (AP-1) and accounts for altered activation-induced CREM expression in T cells from patients with systemic lupus erythematosus.

Thomas Rauen, Konrad Benedyk, Yuang-Taung Juang, Claus Kerkhoff, Vasileios C Kyttaris, Johannes Roth, George C Tsokos, Klaus Tenbrock

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. SLE-Associated Defects Promote Altered T Cell Function.Critical reviews in immunology · 2017
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Thomas RauenDivision of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA.
Konrad Benedyk
Yuang-Taung Juang
Claus Kerkhoff
Vasileios C Kyttaris
Johannes Roth
George C Tsokos
Klaus Tenbrock
Institute of Immunology · HRBeth Israel Deaconess Medical Center · USHarvard University · USUniversity of Münster · DE

Funding

NFAT/AP-1 cooperation in SLE T cellsK23AR055672 · NIAMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KYTTARIS, VASILEIOS CHRISTOS · 2008 to 2012
$486k
NIAMS NIH HHS K23 AR055672
6 · The paper itself

Abstract

The transcriptional repressor cAMP response element modulator (CREM) α has important roles in normal T cell physiology and contributes to aberrant T cell function in patients with systemic lupus erythematosus (SLE). Recently, we characterized a specificity protein-1-dependent promoter located upstream of the CREM gene that accounts for increased basal CREM expression in SLE T cells and reflects disease activity. Here, we identify a novel intronic CREM promoter (denoted P2) in front of the second exon of the CREM gene that harbors putative binding sites for TATA-binding proteins and the transcriptional activator AP-1. DNA binding studies, chromatin immunoprecipitation, and reporter assays confirmed the functional relevance of these sites, and T cell activation through CD3/CD28 stimulation or phorbol 12-myristate 13-acetate/ionomycin treatment enhances P2 promoter activity. Although the basal CREM levels are increased in T cells from SLE patients compared with healthy controls, there are remarkable differences in the regulation of CREM expression in response to T cell activation. Whereas T cells from healthy individuals display increased CREM expression after T cell activation, most likely through AP-1-dependent up-regulation of the P2 promoter, SLE T cells fail to further increase their basal CREM levels upon T cell activation due to a decreased content of the AP-1 family member c-Fos. Because CREM trans-represses c-fos transcription in SLE T cells, we propose an autoregulatory feedback mechanism between CREM and AP-1. Our findings extend the understanding of CREM gene regulation in the context of T cell activation and disclose another difference in the transcriptional machinery in SLE T cells.

Indexed as

Lymphocyte ActivationUp-RegulationCarcinogensCD28 AntigensCD3 ComplexCyclic AMP Response Element ModulatorExonsHumansIonomycinIonophoresLupus Erythematosus, SystemicProto-Oncogene Proteins c-fosTetradecanoylphorbol AcetateT-LymphocytesTranscription Factor AP-1CarcinogensCD28 AntigensCD3 ComplexCREM protein, humanCyclic AMP Response Element ModulatorIonomycinIonophoresProto-Oncogene Proteins c-fosTetradecanoylphorbol AcetateTranscription Factor AP-1

Identifiers

PMID21757709
PMCPMC3173235
OpenAlexW2010543739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.